Comparison of Clinical, Metabolic, Hormonal, and Ultrasound Parameters among the Clomiphene Citrate-Resistant and Clomiphene Citrate-Sensitive Polycystic Ovary Syndrome Women.
Anti-Müllerian hormone
Ferriman–Gallwey score
clomiphene
metabolic syndrome
polycystic ovary syndrome
Journal
Journal of human reproductive sciences
ISSN: 0974-1208
Titre abrégé: J Hum Reprod Sci
Pays: India
ID NLM: 101473512
Informations de publication
Date de publication:
Historique:
entrez:
3
10
2019
pubmed:
3
10
2019
medline:
3
10
2019
Statut:
ppublish
Résumé
The objective of the study is to compare the clinical, metabolic, hormonal, and ultrasound parameters among the clomiphene citrate (CC)-sensitive and CC-resistant polycystic ovary syndrome (PCOS) women. This was a prospective observational study. The study was conducted at the infertility outpatient department in a government hospital. A total of 164 women with PCOS-related infertility were included. Incremental dose of CC from 50 mg/day to 100 mg/day to 150 mg/day over three cycles was given. Ovulation was the outcome. Those who failed to ovulate with 150 mg CC were CC resistant. Of the total 164 PCOS women, 88 (53.7%) were CC resistant and 76 (46.3%) were CC sensitive. Of the 76 PCOS women who ovulated, maximum, i.e., 37 (22.6%) women ovulated with 100 mg CC. The most common diagnostic feature of PCOS in this study was hyperandrogenism (96.3%). CC-resistant PCOS women had significantly higher weight, waist circumference, waist-hip ratio, and body mass index (BMI). Significantly longer menstrual cycles and hyperandrogenism were significantly more common in CC-resistant group. CC-resistant group had a significantly higher ovarian reserve (ovarian volume, antral follicle count, and anti-Müllerian hormone values). Baseline luteinizing hormone (LH) values and LH-follicle stimulating hormone ratio were significantly higher in the CC-resistant group. Clomiphene-resistant PCOS women have significantly higher hyperandrogenism, longer cycles, more deranged metabolic profile, higher BMI, and ovarian reserve. These differences should be kept in mind while deciding the ovulation induction protocol.
Identifiants
pubmed: 31576079
doi: 10.4103/jhrs.JHRS_89_18
pii: JHRS-12-216
pmc: PMC6764232
doi:
Types de publication
Journal Article
Langues
eng
Pagination
216-223Informations de copyright
Copyright: © 2019 Journal of Human Reproductive Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Lancet. 2007 Aug 25;370(9588):685-97
pubmed: 17720020
J Clin Endocrinol Metab. 2005 Jul;90(7):4112-4
pubmed: 15827102
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Fertil Steril. 2009 Feb;91(2):456-88
pubmed: 18950759
Eur J Clin Nutr. 2010 Jan;64(1):2-5
pubmed: 19935820
Int J Gynaecol Obstet. 2016 Apr;133(1):59-63
pubmed: 26848057
J Reprod Med. 2015 Nov-Dec;60(11-12):495-500
pubmed: 26775457
Saudi Med J. 2016 Nov;37(11):1272-1275
pubmed: 27761570
Hum Reprod. 2004 Jan;19(1):41-7
pubmed: 14688154
Clin Exp Reprod Med. 2014 Jun;41(2):80-5
pubmed: 25045632
Hum Reprod. 2009 Aug;24(8):2007-13
pubmed: 19401323
J Hum Reprod Sci. 2013 Jan;6(1):15-8
pubmed: 23869144
Fertil Steril. 2003 Jul;80(1):143-5
pubmed: 12849816
Int J Reprod Biomed (Yazd). 2016 Dec;14(12):743-754
pubmed: 28331909
Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S460-4
pubmed: 23565467
Am Fam Physician. 2009 Apr 15;79(8):671-6
pubmed: 19405411
Indian J Med Res. 2015 Sep;142(3):238-40
pubmed: 26458338
Syst Rev. 2017 Dec 22;6(1):264
pubmed: 29273090
Int J Gynaecol Obstet. 2001 Oct;75(1):43-50
pubmed: 11597618
World J Diabetes. 2011 Mar 15;2(3):33-40
pubmed: 21537458
J Ovarian Res. 2016 Feb 11;9:3
pubmed: 26864649
Indian J Med Res. 2011 Oct;134:440-6
pubmed: 22089604